AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b
December 10, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announces strong topline results from the Phase 2a portion of its GOAL-HF1 clinical study program evaluating AC01 in patients with heart failure and reduced ejection fraction (HFrEF). AC01 demonstrated a favorable safety and tolerability profile and […]